Ability Pharmaceuticals announces that the United States Food and Drug Administration (FDA) has approved the phase I/IIa study to assess the efficacy and safety of ABTL0812 in combination with gemcitabine and nab-paclitaxel in patients with advanced metastatic pancreatic cancer at first line therapy and as maintenance after chemotherapy.

This milestone comes after FDA approval of the Investigational New Drug (IND) for endometrial or squamous non-small cell lung cancer last December. In Septembre the EMA had designated it as an orphan drug.

"We are now working with the medical community to start the clinical development of ABTL0812 in this condition" says Dr Carles Domènech, CEO of Ability.

More information is available on the Ability Pharma website.